home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Genetic News | search  
 

INTERNATIONAL RETT SYNDROME ASSOCIATION - PERMANENT RESEARCH FUND

 
  June, 1 2000 16:53
your information resource in human molecular genetics
 
     

INTERNATIONAL RETT SYNDROME ASSOCIATION


PERMANENT RESEARCH FUND



SUBMISSION DEADLINES: JANUARY 15, JULY 15



In most circumstances, IRSA grants will be up to $40,000 with two competing renewals possible. For larger grants, special permission should be obtained prior to submission.



SMALL GRANTS


    • Hypothesis based proposals

    • Can be high-risk, high-reward

    • To obtain pilot data

    • A traditional NIH type proposal



SUPPLEMENTAL GRANTS


    • To enhance and extend existing NIH funded studies

    • To add a student, fellow or staff to ongoing RS studies

    • To add a RS component to related studies

TRANSLATIONAL RESEARCH

    • Studies to enable basic research findings to move towards clinical application and treatment

    • Need not be hypothesis-based

For further information, go to:



http://www.rettsyndrome.org/main/Types_of_Grants_research_fund_.htm


____________________________________________________________


RETT SYNDROME is a brain disorder which appears primarily girls after a period of early normal development until six to 18 months of age. A period of regression follows during which acquired speech and hand skills are lost, and seizures, repetitive hand-wringing or hand-washing movements, irregular breathing and motor-control problems develop. Individuals with RS can live to adulthood, but most never regain the ability to use their hands or to speak.


In October of 1999, the discovery of a genetic mutation (MECP2) on the X chromosome (Xq28) revealed significant insight into the cause of Rett syndrome,. Continued research is now focused on still unidentified genetic factors which may contribute to RS. The gene instructs cells throughout the body to make a protein known as methyl-CpG binding protein-2 or MeCP2. In the nuclei of cells, the head of the MeCP2 protein attaches directly to the methylated DNA in control regions of target genes, while the tail fastens to a large complex of proteins that compact the target gene and keep it silent. This is the first instance of a human disease caused by defects in a protein whose function it is to silence other genes.


Message posted by: Frank S. Zollmann

print this article mail this article
Bookmark and Share this page (what is this?)

Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.

Use the links below to share this article on the social bookmarking site of your choice.

Read more about social bookmarking at Wikipedia - Social Bookmarking

Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2016 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.